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Progressive kidney fibrosis precedes end-stage renal failure
in up to a third of patients with diabetes mellitus. Elevated
intra-renal transforming growth factor-b (TGF-b) is thought to
underlie disease progression by promoting deposition of
extracellular matrix and epithelial–mesenchymal transition.
GW788388 is a new TGF-b type I receptor inhibitor with a
much improved pharmacokinetic profile compared with
SB431542. We studied its effect in vitro and found that it
inhibited both the TGF-b type I and type II receptor kinase
activities, but not that of the related bone morphogenic
protein type II receptor. Further, it blocked TGF-b-induced
Smad activation and target gene expression, while
decreasing epithelial–mesenchymal transitions and
fibrogenesis. Using db/db mice, which develop diabetic
nephropathy, we found that GW788388 given orally for
5 weeks significantly reduced renal fibrosis and decreased
the mRNA levels of key mediators of extracellular matrix
deposition in kidneys. Our study shows that GW788388
is a potent and selective inhibitor of TGF-b signalling
in vitro and renal fibrosis in vivo.
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Diabetic nephropathy leads to end-stage renal failure in
20–30% of patients with type 1 or type 2 diabetes mellitus.1
The multifunctional cytokine, transforming growth factor-b
(TGF-b), is elevated in patients with diabetic nephropathy
and is likely a prime mediator in the progression of renal
disease.2,3
Specimens from patients with diabetic nephropathy show
elevated TGF-b mRNA and protein levels in glomeruli
and the tubulointerstitium.4 Also, urinary and serum levels
of TGF-b are significantly increased in diabetes patients.5 In
experimental animal models of type 1 and type 2 diabetes,
similar patterns of increased TGF-b expression and secretion
have been observed.6 Nuclear accumulation of downstream
TGF-b effector proteins was observed in diabetic kidneys.
Furthermore, elevated levels of the TGF-b type II receptor
(TbRII) have been reported in diabetic mice compared with
non-diabetic controls.7
One of the mechanisms by which TGF-b induces fibro-
genesis is through stimulation of extracellular matrix (ECM)
proteins and inhibition of matrix degradation. Expression of
key matrix components is enhanced upon TGF-b treatment,
both in glomerular mesangial cells and renal tubular
epithelial cells.8–11 These factors include fibronectin (FN),
type I collagen (COL-1), type III collagen (COL-III), type IV
collagen (COL-IV) and laminin.12 TGF-b further stimulates
ECM accumulation through enhancing expression of connec-
tive tissue growth factor, which in turn induces FN and
COL-III expression.13 Also, activated TGF-b suppress the
activity of matrix metalloproteinases14 through increased
expression of tissue inhibitor of metalloproteinases and
plasminogen activator inhibitor 1 (PAI-1).15 Thus, TGF-b
promotes renal fibrogenesis by increasing the synthesis of
ECM components and inhibiting matrix degradation.
An additional cellular pathomechanism whereby TGF-b
promotes fibrosis is through the mediation of epithelial to
mesenchymal transition (EMT), a process whereby polarised
epithelial cells are transformed into highly migratory fibro-
blastoid cells. Epithelial cells lose polarity, epithelial markers,
and cell–cell contact. The cells undergo cytoskeletal remodel-
ling and gain mesenchymal markers essential for cell–ECM
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association. The net result being enhanced cell motility and
invasiveness.16,17 In renal fibrosis, the pathological signifi-
cance of tubular EMT has become increasingly recognised.
Epithelia can contribute to the ECM overproduction by
creating new fibroblasts through the induction of EMT.18
TGF-b and the superfamily members, activins nodal and
bone morphogenic proteins (BMPs), signal through related
type I and type II transmembrane serine/threonine kinase
receptors. The kinases act in sequence, with the ligand-
specific type I receptor acting as a substrate for the type II
receptor. In most cell types, TGF-b signals via the TGF-b type
I receptor also termed activin receptor-like kinase (ALK)5.19
In endothelial cells, however, TGF-b signals via ALK1 and
ALK5.20 In contrast, BMP signals through ALK2, ALK3, or
ALK6 and activin, and nodal through ALK4 and ALK7.21,22
For TGF-b/ALK5 and activin, the signal is transduced into
the cytoplasm through phosphorylation of the receptor-
regulated Smads (R-Smads), Small phenotype and mothers
against DPP-related protein (Smad)2, and Smad3. For TGF-
b/ALK1 and BMP, the signal is via phosphorylation of the
R-Smads, Smad1, 5, and 8.23 Phosphorylated and activated
R-Smads dissociate from the receptor complex and associate
with Smad4 in a heteromeric manner. The activated com-
plexes shuttle to and accumulate in the nucleus. Here they
regulate expression of a large array of genes in a cell-type-
specific and ligand dose-dependent manner.24
To directly address the therapeutic potential of TGF-b
inhibitors in renal disease, small-molecule competitive
antagonists of the ALK5 kinase activity have been developed.
These inhibitors interact with the ATP-binding site, thereby
preventing phosphorylation of Smad proteins.25,26 The com-
monly used ALK5 inhibitor, 4-(5-benzo[1,3]dioxol-5-yl-4-
pyridin-2-yl-1H-imidazol-2-yl)-benzamide (SB431542), is an
ATP competitive kinase inhibitor.27 Another mechanism for
abrogating TGF-b signalling has been through long-term
treatment with monoclonal anti-TGF-b antibody. In diabetic
rodents, this effectively prevented glomerulosclerosis and
renal insufficiency.7,11,28,29 Also, antisense TGF-b oligo-
nucleotides were found to reduce kidney weight and expres-
sion of matrix components in diabetic mice.30 Recently, a
soluble fusion protein of the TbRII was reported to reduce
albuminuria in a chemically induced model of diabetic
nephropathy in rats.31
A limited number of studies have been reported on the use
of small-molecule inhibitors of TGF-b signalling in vivo.32,33
SB525334 was shown to significantly reduce procollagen
1a(I), in rat kidneys, in an induced model of nephritis.34 Also
the inhibitor IN-1130 reduced obstructive nephropathy in
rats.35 These data provide a strong foundation for using type
I receptor kinase inhibitors in clinical testing.
Recently, 4-(4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-
2-yl)-N-(tetrahydro-2Hpyran-4-yl) benzamide (GW788388)
was developed, as an alternative to the ALK5 inhibitor,
SB431542, with better in vivo exposure (Figure 1). GW788388
is orally active and has a good pharmacokinetic profile,
with an elimination half-life of 1.3 h and a systemic plasma
clearance of 20 ml min1 kg1 in rats. It was previously shown
to reduce the fibrotic response in a chemical induced model of
fibrosis in rats and improve liver histology.32
In this study, we further characterised the potency and
selectivity of this novel inhibitor, GW788388. We show that
this compound effectively blocks both the ALK5 and to some
extent the TbRII. In renal epithelial and cancer cell lines, we
assess the inhibitory effects on TGF-b-mediated biological
responses such as EMT and fibrogenesis. We examine the
effect of blocking TGF-b signalling on renal fibrosis and
kidney function in the db/db mouse model of spontaneous
diabetic nephropathy, resembling the pathogenic phenotype
observed in patients with type 2 diabetes mellitus. We show
that GW788388 effectively inhibits TGF-b signalling in vitro
and reduces renal fibrosis in vivo.
RESULTS
GW788388 is a selective inhibitor of ALK5 and TbRII
Structures of GW788388 and SB431542, two ATP competi-
tive inhibitors of the kinase domain of ALK5, are shown in
Figure 1a. In a biochemical binding assay, using the intra-
cellular kinase domain of ALK5, GW788388 was found
to have an IC50 for GST-ALK5 of 0.018±0.08 mM.
32 To test
the specificity of GW788388, we performed an in vitro kinase
assay on full-length constitutively actively signalling recep-
tors. Human embryonic kidney 293T cells were transiently
transfected with expression plasmids encoding constitutively
active ALK (caALK)5, TbRII, BMPRII, or activin type II
receptor (ActRII). Receptors were immunoprecipitated and
challenged with g-32P-labelled ATP and 10mM of compounds.
GW788388 potently inhibited autophosphorylation of ALK5,
TbRII, and to some extent ActRII (Figure 1b). The compound
had no effect on the BMP type II receptor kinase activity.
To address if GW788388 was cytotoxic, we treated cells
with a dilution range of the compound and measured cell
viability after 72 h. GW788388 showed no toxicity in Namru
murine mammary gland (NMuMG) (Figure 1c), MDA-MB-
231, renal cell carcinoma (RCC)4, and U2OS cells (data not
shown) when treated with dilutions from 4 nM to 15 mM.
Similar results were obtained with the SB431542 inhibitor
(Figure 1c).
GW788388 inhibits TGF-b-induced Smad2 phosphorylation
and Smad2/3 nuclear translocation
Since GW788388 could block the kinase activity of ALK5
and TbRII, we next studied the inhibitory effect on TGF-b,
activin, and BMP-induced R-Smad phosphorylation and
nuclear translocation. GW788388 inhibited TGF-b-induced
Smad2 phosphorylation in a dose-dependent manner in
NMuMG (Figure 2a; Figure S1a), MDA-231-MB (Figure 2b),
and renal cell carcinoma (RCC4)/von Hippel Lindau (VHL)
(data not shown). TGF-b-mediated Smad1/5 phosphory-
lation, which requires ALK5 and TbRII, was also inhibited by
GW788388 (Figure 2a and b). In T47D cells, GW788388 and
SB431542 inhibited the activin-induced phosphorylation of
Smad2 (Figure 2c).
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Upon phosphorylation, R-Smads form complexes with
Smad4 and accumulate in the nucleus. TGF-b-induced
Smad2/3 nuclear translocation was dose-dependently inhi-
bited when NMuMG cells were treated with GW788388
(Figure 2d). We tested if GW788388 inhibited the BMP-
signalling cascade by analyzing the effect of the compound
upon BMP-induced phosphorylation of Smad1/5. As shown
in Figure 2e, GW788388 had no inhibitory effect on Smad1/5
phosphorylation by BMP. SB431542 was shown to have some
inhibitory effect on the mitogen-activated protein kinase
p38a at 10 mM.25 We therefore tested whether GW788388
could inhibit sorbitol-activation of stress-induced kinases
such as the mitogen-activated protein kinases p38 and ERK
1/2. GW788388 had no inhibitory effect on these mitogen-
activated protein kinases (data not shown). Thus, GW788388
selectively inhibits TGF-b and activin Smad signalling and
not the closely related BMP-signalling cascade.
GW788388 selectively inhibits ALK4, ALK5, and ALK7
To further confirm the selectivity of GW788388, U2OS cells
were transiently transfected with expression plasmids encod-
ing the constitutively active full-length receptors caALK2,
caALK3, caALK4, caALK5, caALK6, and caALK7.36 These
mutationally active receptors signal independently of ligand
and their type II receptors. They were cotransfected with the
corresponding luciferase reporter constructs. The TGF-b-
inducible reporter CAGA12-Luc contains Smad-responsive
elements from the PAI-1 promoter, which specifically bind
Smad3/Smad4 and drive the luciferase reporter gene.37 The
BMP-inducible luciferase reporter, BMP-responsive element-
Luc, contains a BMP-responsive elements from the inhibitor
of DNA-binding 1 promoter.38
GW788388 inhibited the TGF-b response, very efficiently,
by blocking signalling through caALK5, caALK4, and caALK7
in a dose-dependent manner (Figure 3a). The SB431542
inhibitor was used for comparison and similar results were
obtained with all caALKs (data not shown). In agreement
with the phosphorylation data, GW788388 had no inhibitory
effect on the constitutively active BMP receptors (Figure 3b).
In addition, TGF-b and activin (Figure S1b) but not BMP-
induced reporter activity was blocked by GW788388 (data
not shown). Thus, GW788388 is a selective inhibitor of the
TGF-b type I receptors ALK5, ALK4, and ALK7.
GW788388 inhibits TGF-b-induced EMT and growth inhibition
In epithelial cells, the TGF-b-mediated growth inhibitory
response and EMT are two cellular processes that have been
extensively explored. The NMuMG cells are a widely used
in vitro model system for studying these TGF-b-mediated
responses.39 To test if GW788388 could inhibit the TGF-b-
induced growth inhibitory response, we measured cell proli-
feration with serial dilutions of GW788388. As shown in
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Figure 1 | GW788388 inhibits both ALK5 and TbRII. (a) Chemical structures of GW788388, 4-(4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl] pyridin-2-yl)-
N-(tetrahydro-2Hpyran-4-yl) benzamide and SB431542, 4-(5-benzo[1,3] dioxol- 5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)-benzamide. (b) Effect of
GW788388 and SB431542 on autophosphorylation of caALK5, TbRII, ActRII, and BMP type II receptor kinase activity. Human embryonic kidney
293T cells were transfected with plasmids encoding full-length receptors. Type II receptors can signal independently of ligand. Receptors were
immunoprecipitated and the in vitro kinase assays were performed with g-32P-labelled ATP in the presence of 10 mM GW788388 (GW) or 10mM
SB431542 (SB). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. (c) Cell viability assay. NMuMG cells
were treated with dilutions of GW788388 (squares) and SB431542 (triangles) for 72 h. Viability was measured with a modified MTS assay,
measuring metabolically active cells.49 Data are presented as % inhibition compared with vehicle control. Bars represent mean±s.e.m.
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Figure 4a, increasing concentrations of GW788388 inhibits
TGF-b-induced growth inhibition. These results were further
supported by light microscopy images, demonstrating
detachment of NMuMG cells from the tissue culture surface
in response to TGF-b treatment, suggestive of programmed
cell death (Figure 4b). Thus, GW788388 blocked TGF-b-
mediated growth arrest.
With phase-contrast microscopy, we observed the transi-
tion of the cells from an epithelial to a fibroblastoid
phenotype upon stimulation with TGF-b for 48 h (Figure
4b). In cells stained by immunofluorescence with epithelial
and mesenchymal markers, we observed actin stress fiber
formation (Figure 4c), loss of E-cadherin expression at
cell–cell junctions, and gain of N-cadherin expression (data
not shown) in response to TGF-b treatment. This EMT
response, mediated by TGF-b, was completely inhibited with
GW788388 (Figure 4b and c).
We confirmed these visual observations by analyzing
protein and mRNA expression by western blot analysis and
semi-quantitative reverse transcriptase-polymerase chain reac-
tion. In NMuMG and RCC4/VHL cells, we analyzed the
changes in the expression of epithelial and mesenchymal
markers after 48 h of TGF-b stimulation (Figure 5). E-cadherin
protein expression was reduced upon TGF-b treatment, whereas
the expression of the mesenchymal markers N-cadherin and
a-smooth muscle actin was increased (Figure 5a and b).
GW788388 attenuated these TGF-b-induced EMT responses.
The inhibitory effect of GW788388 was also observed on mRNA
levels of critical TGF-b target genes involved in EMT, such as
E-cadherin, FN, and the transcriptional repressor of E-cadherin,
SNAIL (Figure 5c). In conclusion, GW788388 blocks the
TGF-b-induced growth inhibitory and EMT response.
GW788388 inhibits the TGF-b-induced fibrotic responses
in vitro
Since GW788388 inhibited important TGF-b-induced target
gene responses required for EMT, we sought to examine
whether the drug also could inhibit TGF-b responses
involved in ECM remodelling. We investigated this by
quantitative reverse transcriptase-polymerase chain reaction
and western blot analysis. We found that GW788388 could
prevent the TGF-b-induced upregulation of connective tissue
TGF-β
Control +
+
+
+
+
+
+ +
+
+
+
+
+
+
+
+
+
+
SB (10 µM)
GW (10 µM)
GW (5 µM)
GW (1 µM)
Actin
Actin
ActinU
2O
S
TubulinT
47
D
N
M
uM
G
M
D
A-
23
1-
M
B
Smad2/3
Smad2/3
Smad2/3
P-Smad1/5
P-Smad1/5
P-Smad1/5
P-Smad2
Control
P-Smad2
P-Smad2
1 µM
TGF-β
5 µM
Ab: Smad2/3
DMSO
TGF-β
Control +
+
+
+
+
+
+
+ + + + + +
+
+
+
+
+
SB (10 µM)
GW (10 µM)
GW (5 µM)
GW (2.5 µM)
DMSO
Control
Activin A
+
+
+
+
+
+
+
+ + + +
+
+
+
+SB (10 µM)
GW (1 µM)
GW (5 µM)
GW (10 µM)
+
+
+
+
+
+
+
+
++++
Control
BMP
SB (10 µM)
GW (10 µM)
DMSO
e
Figure 2 | GW788388 inhibits TGF-b-induced Smad activation dose-dependently. NMuMG (a) and MDA-MD-231 cells (b) were treated
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growth factor, PAI-1, and COL-I mRNA expression in the
renal epithelial cells RCC4/VHL (Figure 6a) and FN in
NMuMG cells (Figure 5c). On protein levels, we confirmed
that GW788388 blocks the TGF-b-induced expression of
COL-I and FN (Figure 6b). Thus, GW788388 inhibits the
TGF-b-mediated expression of important players in fibro-
genesis both on mRNA and protein levels.
GW788388 potently attenuates renal fibrosis in vivo
We have demonstrated that GW788388 is a potent inhibitor of
TGF-b signalling in several in vitro models. We next examined the
effects of GW788388 in vivo. First, we compared the intravenous
pharmacokinetic profiles of GW788388 with SB431542 in
Sprague–Dawley rats. Clearance was 34±12.2 ml min1 kg1
for GW788388 versus 37.5±13.5 ml min1 kg1 for SB431542.
The half-life of GW788388 was 4.1±1.8 h versus 28.5±16.1 min
for SB431542 (data not shown), making GW788388 far more
suitable for in vivo use than SB431542.
The db/db mouse model of spontaneous diabetic nephro-
pathy was chosen for further in vivo characterisation of
GW788388. Six-month-old mice were used, with advanced-
stage renal disease, significant glomerular changes, and
elevated albuminuria.40 Mice were treated with oral admin-
istration of 2 mg kg1 day1 of GW788388 for 5 weeks. No
adverse side effects were observed with the treatment. Figure
7a shows diabetic mouse kidneys stained with Masson’s
Trichrome stain. Collagen deposits are observed in blue.
Robust collagen deposits were seen in glomeruli and minimal
to mild glomeropathy was evident in most diabetic animals
(left panel). Treatment with GW788388 at 2 mg kg1 day1
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resulted in a reduced collagen staining (Figure 7a, right
panel). Glomerulopathy was assessed independently in picric
acid stain-stained sections, scored blinded. Diabetic mice had
significant glomerulopathy marked by mesangial matrix
expansion, mesangial hypertrophy, proliferation, and glo-
merular basement membrane thickening. This was signifi-
cantly reduced when treated with GW788388 (Figure 7b).
Urinary albumin excretion was additionally measured and
corrected for creatinine concentrations. In diabetic mice,
urinary albumin levels were significantly elevated (Figure 7c).
GW788388 appeared to decrease urinary albumin concentra-
tions, although not statistically significant, suggesting that the
underlying glomerular dysfunction persisted in the treated
animals. To confirm that the observed changes, in glomer-
ulopathy and the trend for reduced albuminuria, correlated
with inhibition of TGF-b target genes in vivo, RNA was
extracted from whole kidneys and the levels of matrix
mRNAs examined. FN, COL-I, PAI-1, and COL-III expres-
sion levels were significantly increased in diabetic mice as
compared with their lean littermates (Figure 7d). Treatment
with 2 mg kg1 day1 of GW788388 significantly reduced the
mRNA levels of PAI-1, COL-I, and COL-III to nearly the
same levels as seen in the non-diabetic lean littermates. Taken
together, these results indicate that GW788388 attenuates
TGF-b signalling in vivo and effectively reduces hallmarks
of fibrogenesis in mice suffering from late-stage diabetic
nephropathy.
DISCUSSION
TGF-b is suggested to be a key factor in the generation of
tissue fibrosis.8,28,29,41 In the diabetic kidney, TGF-b plays an
important role in early and late manifestations of nephro-
pathy such as renal hypertrophy and mesangial matrix
expansion.7 These pathomechanisms result in destruction
of functional renal tissue and eventually loss of renal
function. Blocking TGF-b signalling is therefore considered
a promising therapeutic approach in the treatment of renal
disease. We studied a new TGF-b inhibitor, GW788388
(results are summarised in Figure 8). We show that
GW788388 effectively inhibits TGF-b-mediated responses
in vitro by blocking the kinase activity of both type I and
type II receptors. Importantly, we show that oral administra-
tion of GW788388 to diabetic mice significantly reduces
glomerulopathy in kidneys and attenuates expression of key
components involved in fibrosis. This is consistent with a
previous study showing that GW788388 reduced fibrosis
markers in the kidney following puromycin-induced nephro-
pathy.33 These results encourage further studies to therapeu-
tically target the TGF-b pathway in order to treat renal diseases.
GW788388 was identified as an orally active ALK5 inhi-
bitor, with much improved in vivo exposure compared with
SB431542.25,32 In order to study the specificity of the
compound, we performed an in vitro kinase assay with 32P-
labelled ATP. We found that GW788388 potently inhibits
both the ALK5, TbRII and to some extent the ActRII kinase
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receptor activities but not the BMP type II receptor. This
contrasts what is seen for the related inhibitor, SB431542.20,25
As a consequence of inhibiting the TGF-b receptors, we
found that TGF-b-induced Smad2 phosphorylation and
nuclear accumulation were potently blocked by GW788388.
The specificity of GW788388 was further tested on all seven
activated ALKs with reporter assays. We show that the
compound could inhibit ALK5 along with the structurally
similar receptors, that is, ALK4 and ALK7. GW788388 did
not inhibit ALK2, ALK3, and ALK6. Previous studies using
other TGF-b type I receptor inhibitors have shown similar
results,34,42,43 the main distinction being that GW788388 in
addition targets the TbRII kinase activity. The additional
activity against the TbRII kinase should not alter the selec-
tivity profile or the potency of an ALK5 inhibitor as long as
the ALK5 kinase binding is stronger than to the type II
receptor.
TGF-b induces a growth inhibitory and an EMT response
in NMuMG cells.39,44 We show that GW788388 dose depen-
dently inhibits these TGF-b responses. The TGF-b-mediated
upregulation of target genes, involved in excess ECM
deposition is well described. Treating renal epithelial cells
with TGF-b mimics the fibrotic response seen in renal
disease, where mRNA levels of PAI-1 and COL-I are increased
by TGF-b treatment.11 In our hands, GW788388 could
prevent the TGF-b-mediated upregulation of connective
tissue growth factor, PAI-1, and COL-I RNA levels, and FN
and COL-I on protein levels in the renal epithelial cell line
RCC4/VHL. Recently, SNAIL was described to directly induce
renal fibrosis and strong expression was found in fibrotic
human kidney sections.45 With GW788388 we could block
SNAIL mRNA expression in epithelial cells. Taken together,
these data indicate that GW788388 selectively and efficiently
inhibits TGF-b-mediated responses in vitro.
Since GW788388 inhibits important components in the
TGF-b-induced fibrotic response in cell models, we hypo-
thesised that GW788388 could reduce markers of fibrosis in
a mouse model of diabetic nephropathy. Our aim was to
examine if TGF-b receptor inhibition could be effective in
older mice with established renal disease, as would be
observed in patients presenting with impaired renal function.
We show that oral administration of GW788388 for 5 weeks
in 6-month-old db/db mice significantly attenuated glomer-
ulopathy in mouse kidneys. This correlated with reduced
mRNA expression of critical factors in ECM remodelling,
namely PAI-1, COL-I, and COL-III, by GW788388. These
results are in agreement with the oral administration of
GW788388 to rats with chemically induced liver and renal
fibrosis,32 and with db/db mice treated with neutralising
anti-TGF-b antibodies.7
Despite ALK5 inhibition having inhibitory effects on
fibrogenesis and histological glomerulopathy, the effects on
kidney function were not significant. Only a trend for a
reduction in urinary excretion of albumin was observed.
Longer treatments regimes may be necessary to reverse the
effects of fibrosis. Moreover, it is not clear if ALK5 inhibition
would address the underlying glomerular pathology leading
to albuminuria in the first instance. Thus, for ALK5 inhi-
bition alone to be fully effective against a change in glome-
rular permeability, we hypothesise that earlier and longer
treatment periods are needed in order to inhibit tissue
remodelling within the kidney and allow restoration and/or
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preservation of glomerular morphology and function. These
results suggest that once renal fibrosis is established,
restoration of function is likely to require prolonged therapy
even with effective inhibition of TGF-b-mediated fibrogenic
pathways.
All together, these data provide a strong foundation for
using TGF-b receptor kinase inhibitors in a clinical setting.
Renal disease progresses slowly and halting this process with a
TGF-b receptor inhibitor will presumably require chronic
treatment. However, TGF-b is a pleiotropic cytokine, which
modulates a broad array of processes. The challenge in using
TGF-b receptor inhibitors for antifibrotic treatment will be to
balance the disease-related fibrotic actions against the
immune modulatory, cardiovascular, and tumor suppressor
functions of TGF-b. Also, all ALK5 kinase inhibitors reported
to date inhibit the kinase activity of the ALK4 and
ALK7,22,25,33,43,46 and GW788388 to some extent the ActRII.
Long-term treatment may therefore affect activin- and nodal-
dependent signalling. Further investigation will be needed to
gain insight to the effect of this inhibition.
In summary, we have demonstrated that GW788388 can
inhibit TGF-b and activin signalling in vitro and attenuate
renal fibrosis in vivo (Figure 8). By blocking the action of the
ALK5 and TbRII kinase receptors, TGF-b-induced growth
arrest, EMT, and ECM deposition were inhibited in vitro.
Through oral administration of GW788388 to db/db mice for
5 weeks, we were able to reduce glomerulopathy and prevent
the TGF-b-mediated upregulation of excess renal ECM
deposition. Thus, we could reduce renal fibrosis in a mouse
model for advanced diabetic nephropathy. Our results suggest
that TGF-b receptor kinase inhibition should attenuate
fibrogenesis and improve the fibrotic outcome for patients
suffering from diabetic nephropathy. Whether prolonged or
earlier treatment might restore or prevent declines in renal
function and not just fibrosis remain to be determined.
MATERIALS AND METHODS
Cell culture and reagents
The human breast carcinoma MDA-MB 231 and T47D, the human
osteosarcoma U2OS, and the monkey kidney COS cell lines were
maintained in Dulbecco’s modified Eagle’s medium with 10% fetal
bovine serum, 100 U ml1 penicillin, and 50 mg ml1 streptomycin.
The human renal carcinoma cell line (RCC4) stably expressing the
VHL protein under neomycin selection. The murine epithelial breast
cells NMuMG were maintained in Dulbecco’s modified Eagle’s
medium as above with 10 mg ml1 insulin.44 Cell lines were cultured
at 371C in 5% CO2. SB431542 was from Tocris (Tocris Biosciences,
Ellisville, MO, USA). Compounds were dissolved in dimethyl
sulfoxide (DMSO). We used 5 ng ml1 TGF-b3, 100 ng ml1 BMP6,
and 50 ng ml1, activin A. Antibodies recognising phosphorylated
Smad (Psmad)2 and PSmad1/5 are described in Persson et al.47 and
TbRII antibody has been described in Franzen et al.19 Smad2/3,
N-cadherin, and E-cadherin antibodies were from BD Transduction
Laboratories (Breda, The Netherlands); COL-I antibody was from
Southern Biotechnology (Birmingham, AL, USA); FN antibody was
from Abcam (Cambridge, UK); b-actin (AC-15), a-smooth-muscle
actin (1A4), and FLAGM2 antibodies were from Sigma (St Louis,
MO, USA); hemagglutinin antibody was from Roche.
Cellular assays, immunodetection, and RNA extraction
Immunofluorescence, western blotting, in vitro kinase assay, cell
proliferation assays, transfection, and transcriptional reporter
gene assay were performed as reported previously.20,36–39,48 RNA
extraction, reverse transcriptase-polymerase chain reaction, and
Q-PCR were described in Gellibert et al.32 and Deckers et al.44 For
detailed description see Supplementary Methods.
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Histopathology
Kidneys were fixed in 10% formalin. Sections were stained with
picric acid stain and Masson’s Trichrome at Research Pathology
Services (New Britain, PA, USA). Sections were submitted to
Pathology Associates Inc. for assessment of glomerular changes.
Scoring system is outlined in Supplementary Methods.
Animal experiments
Intravenous pharmacokinetics profiles were determined in Sprague–
Dawley rats using a crossover design on four separate study days
(see Supplementary Methods).
C57BLKS/JLepr db/db mice were used a model for type 2
diabetes mellitus40 (Jackson Laboratory, Bar Habor, Maine, USA).
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Animals received GW788388 at 2 mg kg1 day1 mixed with pow-
dered chow, water ad libitum. After 5 weeks of drug treatment, a
24-h urine collection was performed by individual housing in
metabolic cages. Albumin concentrations corrected for creatinine
were determined (Nephrat II enzyme-linked immunosorbent assay
kit). Kidneys were snap–frozen for RNA analysis. Plasma drug levels
determined by HPLC/MS/MS. GW788388 was isolated from 50ml of
plasma (Sciex API 365). End plasma concentration was 10.4±1.2 nM
and urine concentration 0.9±0.3 mM. All experimental procedures
conformed to the Guide for the Care and Use of Laboratory Animals
published by US Institutes of Health (NIH Publication no. 85–23,
revised 1996), and were approved by the Institutional Animal Care
and Use Committee.
Statistical analysis
The experiment was completely randomised. One-way analysis
of variance was performed with Bonferroni’s multiple comparison
test. Po0.05 was considered to be statistically significant. Mean is
presented either as ±s.e.m. or ±s.d.
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